The federal safety watchdog also OK’d additional 5mm-diameter instruments, the Research Triangle Park, N.C.-based company said. The 3mm instrument open up micro-laparoscopic “virtually scarless” procedures for Senhance, according to TransEnterix.
“The ability to perform microlaparoscopic procedures using 3-millimeter instruments represents an unparalleled shift in the world of robotic surgery and a capability exclusive to the Senhance system,” CEO Todd Pope said in prepared remarks. “The addition of 3-millimeter instruments will allow many high volume surgeries to be performed with smaller incisions, which supports our mission of advancing minimally invasive surgical capabilities within digital laparoscopy.”
“Utilizing 3 millimeter micro instruments on a robotic system represents a new advancement in reducing the invasiveness of many surgeries,” added Dr. Steven McCarus of Florida Hospital Celebration Health. “Patients find such small incisions to be virtually scarless and cosmetically desirable. Surgeons may find that using such tiny instruments with the precision and control of a digital interface makes microlaparoscopy a preferred option to treat more conditions.”
Earlier this month TransEnterix won CE Mark approval in the European Union for the Senhance Ultrasonic instrument system; a bid for U.S. clearance is under way. In September the company put up $33 million for Medical Surgery Technologies and its surgical planning software.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.